Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience

被引：0
|
作者：
Yohannan, Binoy [1 ]
Khan, Hina [1 ]
Cervoni-Curet, Frances [1 ]
Rios, Adan [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; cladribine; low-dose cytarabine; older/unfit AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-100
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [41] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Yao Qin
    Pu Kuang
    Ting Liu
    Clinical and Experimental Medicine, 2023, 23 : 219 - 227
  • [42] Sequential Venetoclax and FLT3 Inhibitors in Combination With Hypomethylating Agents or Low-Dose Chemotherapy in Newly Diagnosed, Unfit, FLT3-Mutant Acute Myeloid Leukemia Patients
    Al Mahmasani, Layal
    Moukalled, Nour
    El Cheikh, Jean
    Bazarbachi, Ali
    Abou Dalle, Iman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S228 - S228
  • [43] Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia
    Jin, Jie
    Chen, Jian
    Suo, Shanshan
    Qian, Wenbin
    Meng, Haitao
    Mai, Wenyuan
    Tong, Hongyan
    Huang, Jian
    Yu, Wenjuan
    Wei, Juyin
    Lou, Yinjun
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1691 - 1697
  • [44] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Qin, Yao
    Kuang, Pu
    Liu, Ting
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 219 - 227
  • [45] Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting
    Piccini, Matteo
    Gianfaldoni, Giacomo
    Mannelli, Francesco
    Scappini, Barbara
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Pilerci, Sofia
    Quinti, Elisa
    Crupi, Francesca
    Guglielmelli, Paola
    Vannucchi, Alessandro Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S285 - S286
  • [46] Safety and Efficacy of Venetoclax (VEN) in Combination With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients (≥65 Years) With Acute Myeloid Leukemia (AML)
    Pratz, K.
    Pollyea, D.
    Jonas, B.
    Pullarkat, V.
    Wei, A.
    Arellano, M.
    Becker, P.
    Frankfurt, O.
    Thirman, M.
    Pigneux, A.
    Recher, C.
    Seymour, J.
    Dvorak, N.
    Xu, T.
    Humerickhouse, R.
    Mabry, M.
    Potluri, J.
    Letai, A.
    DiNardo, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 11 - 12
  • [47] A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy
    Solem, Caitlyn T.
    Bell, Timothy J.
    Kwon, Youngmin
    Cappelleri, Joseph C.
    Johnson, Courtney
    Bhattacharyya, Helen
    Hoang, Caroline J.
    Cortes, Jorge E.
    CANCER, 2020, 126 (19) : 4315 - 4321
  • [48] Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
    Cortes, Jorge E.
    Heidel, Florian H.
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Candoni, Anna
    Leber, Brian
    Sekeres, Mikkael A.
    Pollyea, Daniel A.
    Ferdinand, Roxanne
    Ma, Weidong Wendy
    O'Brien, Thomas
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [49] Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience
    Bertoli, Sarah
    Tavitian, Suzanne
    Bories, Pierre
    Luquet, Isabelle
    Delabesse, Eric
    Comont, Thibault
    Sarry, Audrey
    Huguet, Francoise
    Berard, Emilie
    Recher, Christian
    CANCER MEDICINE, 2019, 8 (08): : 3846 - 3854
  • [50] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Andrew F. Berdel
    Raphael Koch
    Joachim Gerss
    Marcus Hentrich
    Rudolf Peceny
    Tobias Bartscht
    Björn Steffen
    Marina Bischoff
    Karsten Spiekermann
    Linus Angenendt
    Jan-Henrik Mikesch
    Tobias Kewitz
    Trude Butterfass-Bahloul
    Hubert Serve
    Georg Lenz
    Wolfgang E. Berdel
    Utz Krug
    Christoph Schliemann
    Annals of Hematology, 2023, 102 : 63 - 72
12345